Merck's COVID pill is last choice for U.S. patients, global use varies

Merck & Co's new antiviral pill, once touted as a potential game changer for treating COVID-19, is the last choice among four available options for at-risk patients given its relatively low... | January 31, 2022

Related Keywords

New York ,United States ,Philippines ,Milan ,Lombardia ,Italy ,United Kingdom ,New Delhi ,Delhi ,India ,London ,City Of ,Manila ,Bangladesh ,Mumbai ,Maharashtra ,Massachusetts ,Dhaka ,France ,Plattsburgh ,The Philippines ,Ambrish Mithal ,Steve Moore ,Eliav Barr ,Emilio Parodi ,Ruma Paul ,Sayedur Rahman ,Los Angeles ,Ridgeback Biotherapeutics ,Neha Arora ,Alistair Smout ,Onisis Stefas ,Jim Mangia ,Deena Beasley ,Tara Vijayan ,Neil Jerome Morales ,Caroline Humer ,Rajesh Gandhi ,Glaxosmithkline ,Bangabandhu Sheikh Mujib Medical University ,Us Department Of Health ,Northwell Health ,Human Services ,Us National Institutes Of Health ,Department Of Pharmacology ,Gilead Sciences Inc ,Reuters ,Pfizer ,Pfizer Inc ,Family Center ,Well Child ,Central Los ,Wall Street ,Condo Pharmacy ,Bangabandhu Sheikh Mujib Medical ,Max Healthcare ,Massachusetts General ,Los Angeles County ,New York State ,Chief Pharmacy Officer Onisis Stefas ,Reporting By Deena Beasley ,Michael Erman ,Bill Berkrot ,Gilead Sciences ,Nc Stock Exchange ,News ,Information ,Press Release ,Merck ,Few ,Antiviral ,Dance ,Outed ,Us ,Potential ,Name ,Hanger ,Or ,Reating ,The ,Mast ,Choice ,Mong ,Four ,Vailable ,Options ,Patients ,Given ,Its ,Elatively Gild Us3755581036 ,